INXC 6295

Drug Profile

INXC 6295

Alternative Names: INXC 3281

Latest Information Update: 17 Jun 2002

Price : $50

At a glance

  • Originator Inex Pharmaceuticals Corporation
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 17 Jun 2002 Discontinued - Preclinical for Solid tumours in Canada (unspecified route)
  • 23 Apr 1999 Inex has filed an IND application in Canada
  • 20 Oct 1998 A preclinical study has been added to the pharmacodynamics, adverse events and pharmacokinetics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top